ALNYLAM PHARMACEUTICALS, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

ALNYLAM PHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $1.66 billion for the year ending 2025.

  • ALNYLAM PHARMACEUTICALS, INC. showed an increase of +71.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
  • XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 16 years of available data (2010 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 2,121.5%.
  • Historical annual values: Fiscal year 2025: $1.66 billion | Fiscal year 2024: $966.43 million | Fiscal year 2023: $812.69 million | Fiscal year 2022: $866.39 million | Fiscal year 2021: $819.98 million | Fiscal year 2020: $496.58 million | Fiscal year 2019: $547.18 million | Fiscal year 2018: $420.15 million | Fiscal year 2017: $645.36 million | Fiscal year 2016: $193.62 million | Fiscal year 2015: $180.90 million | Fiscal year 2014: $75.18 million | Fiscal year 2013: $53.17 million | Fiscal year 2012: $51.41 million | Fiscal year 2011: $70.23 million | Fiscal year 2010: $74.60 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: